Reimbursement of targeted cancer therapies within 3 different European health care systems

Clinical Therapeutics

Volumn 37, Issue 2, 2015, Pages 474-480

  Mihajlović, Jovan ^a,b   Dolk, Christiaan ^a   Tolley, Keith ^c   Simoens, Steven ^d   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Mihajlović Health Analytics ^*  (Serbia)

^c Tolley Health Economics Ltd   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Europe; health care policy; pharmacoeconomics; reimbursement; Serbia; targeted cancer therapy

Indexed keywords

ORPHAN DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDICATION; DRUG USE; EUROPEAN MEDICINES AGENCY; HEALTH CARE SYSTEM; MOLECULARLY TARGETED THERAPY; NETHERLANDS; PRACTICE GUIDELINE; REIMBURSEMENT; SERBIA; UNITED KINGDOM; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; NEOPLASMS; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; SCOTLAND; SERBIA;

EID: 84923642755     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.12.005     Document Type: Review

References (30)

1. J.S. Ross, D.P. Schenkein, and R. Pietrusko Targeted therapies for cancer 2004 Am J Clin Pathol 122 2004 598 609
2. J. Grillo-López, C. White, and B.K. Dallaire Rituximab: the first monoclonal antibody approved for the treatment of lymphoma Curr Pharm Biotechnol 1 2000 1 9
3. S. Aggarwal Targeted cancer therapies Nat Rev Drug Discov 9 2010 427 428
4. Database of European Medicines Agency. http://www.ema.europa.eu/ema/. Accessed August 15, 2014
5. Database of Food and Drug Administration. http://www.fda.gov/. Accessed August 15, 2014
6. IMS International. Cancer drug innovation surges as cost growth moderates; Report summary. http://www.imshealth.com/. Accessed August 15, 2014
7. A. Aggarwal, and R. Sullivan Affordability of cancer care in the United Kingdom - Is it time to introduce user charges? J Cancer Policy 2 2014 31 39
8. N. Wilking, and B. Jönsson A pan-European comparison regarding patient access to cancer drugs Karolinska Institutet in collaboration with Stockholm School of Economics Stockholm, Sweden 2005
9. National Health Insurance Fund (RFZO). The rule book on criteria for drugs' reimbursment. [in Serbian]. http://www.rfzo.rs/download/pravilnici/lekovi/Pravilnik-kriterijumima-24042014.pdf. Accessed August 15, 2014
10. National Health Insurance Fund (RFZO). Reimbursement lists [in Serbian]. http://www.rfzo.rs/index.php/lekovi-actual56/lista-lekova-05022014. Accessed August 15, 2014
11. Scottish Medicines Consortium (SMC). Home page. https://www.scottishmedicines.org.uk/Home. Accessed August 15, 2014
12. Scottish Medicines Consortium (SMC). Policy statements, a guide to quality adjusted life years. http://www.scottishmedicines.org.uk/About-SMC/Policy-Statements/A-Guide-to-Quality-Adjusted-Life-Years. Accessed August 15, 2014.
13. Scottish Medicines Consortium (SMC). Policy statements, modifiers used in appraising new medicines. https://www.scottishmedicines.org.uk/About-SMC/Policy-Statements/SMC-Modifiers-used-in-Appraising-New-Medicines. Accessed August 15, 2014.
14. National Health Institute of the Netherlands (ZiNL). Home page [In Dutch]. http://www.zorginstituutnederland.nl/. Accessed August 15, 2014.
15. Danish Ministry of Health and Prevention. Analysis of hospital pharmaceuticals: Country report - the Netherlands. http://www.sum.dk/Aktuelt/Publikationer/~/media/Filer%20-%20Publikationer-i-pdf/2009/Landerapport%20Nederlandene%20sygehusmedicin.ashx. Accessed August 15, 2014.
16. National Health Institute of the Netherlands (ZiNL). Voorwaardelijke toelating/financiering van zorg. [In Dutch]. http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/rapporten-en-standpunten/2012/1204-voorwaardelijke-toelating-financiering-van-zorg/Voorwaardelijke+toelating-financiering+van+zorg.pdf. Accessed August 15, 2014.
17. The Dutch Healthcare Council. Bekostiging van add-on geneesmiddelen eenvoudiger per 2015 [In Dutch]. http://www.nza.nl/zorgonderwerpen/zorgonderwerpen/ziekenhuiszorg/nieuws/Bekostiging-van-add-on-geneesmiddelen-eenvoudiger-per-2015/. Accessed November 25, 2014.
18. Statistical Office of the Republic of Serbia. http://webrzs.stat.gov.rs/WebSite/. Accessed August 15, 2014
19. Institute of Public Health of Serbia "Dr Milan Jovanović Batut". http://www.batut.org.rs/index.php?lang=2. Accessed August 15, 2014
20. Scottish Government, National Statistics. http://www.scotland.gov.uk/Topics/Statistics/About. Accessed August 15, 2014
21. Information Services Devision of the NHS National Services Scotland. http://www.isdscotland.org/index.asp. Accessed August 15, 2014
22. Statistics Netherlands. http://statline.cbs.nl/statweb/?LA=en. Accessed August 15, 2014
23. The Netherlands Cancer Registry. http://www.dutchcancerfigures.nl/. Accessed August 15, 2014
24. The European Medicines Agency. Medicines database. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines-landing-page.jsp&mid=. Accessed August 15, 2014
25. National Health Institute of the Netherlands (ZiNL). VOORWAARDELIJK GEFINANCIERDE SPECIALISTISCHE GENEESMIDDELEN. 9th of October, 2014. [In Dutch]: https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/rubrieken/pakket/consultaties/1410-voorwaardelijk-gefinancierde-specialistische-geneesmiddelen/Voorwaardelijk+gefinancierde+specialistische+geneesmiddelen.pdf. Accessed November 25, 2014.
26. http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/pakket/adviescommissie-pakket/adviescommissie-pakket/adviescommissie-pakket/zinl%3Aparagraph%5B3%5D/zinl%3Adocuments%5B%25D/1408-acp - -stukken-ter-kennisneming. Accessed August 15, 2014
27. S. Vegter, M.H. Rozenbaum, and R. Postema Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: Focus on the underlying pharmacoeconomic evaluations Clin Ther 32 2010 1651 1661
28. J. Raftery NICE and the challenge of cancer drugs BMJ 338 2009 b67
29. M.D. Rawlins, and K. Chalkidou The opportunity cost of cancer care: a statement from NICE Lancet Oncol 12 10 2011 931 932 http://dx.doi.org/10.1016/S1470-2045(11)70218-2
30. H.M. Kantarjian, T. Fojo, and M. Mathisen Cancer drugs in the United States: Justum pretium - the just price J Clin Oncol 31 2013 3600 3604